Fig. 2From: Study on the progression types of cancer in patients with breast cancer undergoing eribulin chemotherapy and tumor microenvironmentDifferences in progression types and prognostic analysis. The 33 PPL group had a significantly longer PFS (p = 0.044, log-rank) (a) and OS (p = 0.017, log-rank) (b) compared to the 7 PNM groupBack to article page